Pharmaceuticals, Biotechnology and Life Sciences
Qu Biologics’s first randomized-placebo controlled trial (RCT) resulst, for moderate-to-severe Crohn’s disease (CD) was accepted for publication in Frontiers in Medicine, an open-access peer-reviewed medical journal, as it showed that clinical symptoms of CD can be improved with an immunomodulatory treatment that functions to activate instead of suppress the immune system.
Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only…
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.